Kezar Life Sciences Executive Compensation Details
Ticker: KZR · Form: DEF 14A · Filed: Apr 25, 2025 · CIK: 1645666
| Field | Detail |
|---|---|
| Company | Kezar Life Sciences, INC. (KZR) |
| Form Type | DEF 14A |
| Filed Date | Apr 25, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, proxy-statement, equity-awards
Related Tickers: KZR
TL;DR
Kezar Life Sciences DEF 14A out: Executive pay details for 2024, including equity awards for Dr. Krick & Mr. Fowler.
AI Summary
Kezar Life Sciences, Inc. filed its DEF 14A on April 25, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes information on equity awards granted to executive officers, such as Dr. Krick and Mr. Fowler, and the year-end fair value of outstanding and unvested equity awards.
Why It Matters
This filing provides transparency into how Kezar Life Sciences compensates its top executives, which can influence investor perception and employee morale.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of executive compensation and does not contain new material financial information or strategic changes.
Key Numbers
- 2024-12-31 — Fiscal Year End (Reporting period for executive compensation)
- 20250425 — Filing Date (Date the DEF 14A was submitted)
Key Players & Entities
- Kezar Life Sciences, Inc. (company) — Filer
- Dr. Krick (person) — Executive Officer
- Mr. Fowler (person) — Executive Officer
- 4000 SHORELINE COURT, SUITE 300 (location) — Business Address
- SOUTH SAN FRANCISCO, CA (location) — Business Address
FAQ
What is the primary purpose of this DEF 14A filing?
The primary purpose of this DEF 14A filing is to provide information regarding the solicitation of proxies for the company's annual meeting of stockholders, including details on executive compensation.
Who are the key individuals mentioned in relation to executive compensation?
Key individuals mentioned in relation to executive compensation include Dr. Krick and Mr. Fowler, identified as members associated with equity awards.
What fiscal year does the compensation information primarily cover?
The compensation information primarily covers the fiscal year ending December 31, 2024, with comparative data for prior years.
What type of compensation is detailed in the filing?
The filing details equity awards, including the summary compensation table for applicable years and the year-end fair value of outstanding and unvested equity awards.
Where is Kezar Life Sciences, Inc. headquartered?
Kezar Life Sciences, Inc. is headquartered at 4000 Shoreline Court, Suite 300, South San Francisco, CA 94080.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 25, 2025 by Dr. Krick regarding Kezar Life Sciences, Inc. (KZR).